|
|
ASH 2005 Webcast: New Agents and New Opportunities for Multiple Myeloma Today and TomorrowA Corporate Friday Symposium preceding the 47th Annual American Society of Hematology Meeting
This CME-certified activity addressed current issues in clinical practice in the context of new agents and new discoveries in the treatment of multiple myeloma in an interactive panel discussion with prominent faculty.
|
|
What is role of high-dose melphalan in the era of new effective agents?
|
|
|
Bart Barlogie, MD University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy Little Rock, Arkansas
|
|
|
|
|
Brian G.M. Durie, MD Cedars Sinai Comprehensive Cancer Center Los Angeles, California
|
|
Does the percentage of complete response with new drugs determine ultimate survival?
|
|
|
James D. Cavenagh, MD, MRCP St. Bartholomew's Hospital London, England
|
|
|
|
|
Jean-Luc Harousseau, MD University Hospital Nantes Nantes, France
|
|
Does maintenance improve time to progression and ultimate survival?
|
|
|
Antonio Palumbo, MD Molinette Hospital Turin, Italy
|
|
|
|
|
James D. Cavenagh, MD MRCP St. Bartholomew's Hospital London, England
|
|
Is double transplant better than single transplant?
|
|
|
Jean-Luc Harousseau, MD University Hospital Nantes Nantes, France
|
|
|
|
|
Bart Barlogie, MD University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy Little Rock, Arkansas
|
|
Should known effective therapies or new agents be used in patients with relapsed disease?
|
|
|
Brian G.M. Durie, MD Cedars Sinai Comprehensive Cancer Center Los Angeles, California
|
|
|
|
|
|
The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2005 annual meeting of the American Society of Hematology in San Diego, California. We hope you will find this material informative and useful. |
|
|